Deal intelligence
that closes deals.
Comparable transactions, partner matching, sensitivity analysis, and a negotiation playbook — generated in 60 seconds from 1,900+ real SEC filings.
Configure your report
Select your asset parameters to generate a tailored analysis.
Free preview included · Full report $499 via Stripe
What You Get
A complete deal intelligence package
Not a generic template — every section is calibrated to your exact therapeutic area, modality, phase, and deal type.
Eight Core Analysis Modules
Everything you need for a deal committee presentation
Each module is independently valuable. Together, they give you the most comprehensive deal analysis available outside a top-tier advisory engagement.
Deal Terms Engine
Upfronts, milestones, royalties
Precise benchmarks calibrated to your therapeutic area, modality, and development phase. Median, P25, P75, and maximum values from real transactions.
Comparable Transactions
Your deal in context
The most relevant recent deals matched to your parameters — upfront ratios, total deal values, milestone structures, and royalty tiers side by side.
Partner Intelligence
AI-scored matching + Pharma Intent Score
Every potential partner ranked by therapeutic alignment, pipeline gaps, deal history, geography, and financial capacity — plus our proprietary Pharma Intent Score, a 10-factor predictive model that forecasts which companies are most likely to transact in your space within 12-18 months.
Competitive Landscape
Pipeline mapping
Active competitors in your indication mapped by stage, mechanism, differentiation score, and estimated peak sales. Know exactly where you stand.
Sensitivity & Simulation
Monte Carlo + VaR/CVaR + tornado chart
10,000-iteration Monte Carlo with institutional risk metrics — VaR (95%), CVaR (expected tail loss), skewness, and kurtosis. Tornado chart showing top 5 risks and top 5 upsides. Compound scenario modeling captures non-linear interactions (e.g., CRL + competitor launch, Phase 3 failure + subgroup rescue).
rNPV & Deal Valuation
Probability-weighted asset value
Risk-adjusted NPV with phase-specific PoS across 12 therapeutic areas, TA-specific revenue curves (orphan exclusivity for rare disease, GLP-1 ramp for metabolic), bear/base/bull scenario comparison, real options valuation via CRR binomial lattice, and peak sales sanity check against 164 index drugs across all 12 TAs (Keytruda, Ozempic, Dupixent, Trikafta, and more). Manufacturing WACC premiums for gene therapy, CAR-T, and ADC. Market access delay modeling by TA.
Buyer-Specific Valuation
What your asset is worth to each buyer
Multi-partner comparison showing what up to 3 specific buyers would pay vs. a generic buyer. 5-factor strategic premium model (portfolio fit, deal urgency, patent cliff pressure, pipeline gaps, competitive pressure) with negotiation leverage assessment and timing advantage analysis.
Negotiation Playbook
Data-backed strategy
Where to push, where to concede, and how your structure compares to market norms. Leverage analysis based on buyer pipeline gaps and patent cliff pressure.
How It Works
From parameters to board deck in 60 seconds
Define your asset
Select therapeutic area, modality, development phase, deal type, and indication. Four dropdowns — takes 30 seconds.
Free account — 3 calculations
Review the free analysis
See deal term ranges, comparable deal previews, and a competitive snapshot — instantly. Decide if the full report is worth it.
Full transparency before you pay
Unlock the full report
One click, $499. Get the complete package: partner matching, sensitivity modeling, negotiation playbook, and PDF + Excel exports.
Instant download via Stripe
The Math
$499 vs. the alternative
What it actually costs to build this analysis manually — and what you get for a fraction of the price.
Trusted by deal teams at
Coverage
12 Therapeutic Areas
Every report is calibrated with TA-specific benchmarks, competitive data, and partner pools.
Transaction Types
5 Deal Structures
Differentiated benchmarks for each structure — upfront ratios, milestone allocations, and royalty scalars.
Built For
BD teams that need data, not opinions
Biotech BD & Licensing
- Benchmark term sheets with real transaction data
- Identify the right partner with AI-scored matching
- Build the quantitative case for deal committees
Pharma Search & Evaluation
- Validate internal comps with independent benchmarks
- Screen 850+ companies for therapeutic pipeline fit
- Support investment committee presentations
Biotech Founders & CEOs
- Know what your asset is worth before engaging partners
- Identify buyers with pipeline gaps in your space
- Negotiate from data, not assumptions
Investors & Advisors
- Due diligence on deal economics and structure
- Comparable transaction analysis for valuation
- Market sizing with epidemiological precision
Need unlimited reports?
Pro subscribers get unlimited deal reports, Pharma Intent Score access, priority data, and all 8 calculation engines — $299/month.
FAQ
Common questions
What do I need to generate a report?
Just four inputs: therapeutic area, modality (e.g., small molecule, ADC, gene therapy), development phase, and deal type. The entire process takes about 60 seconds.
What format is the report delivered in?
You get both a board-ready PDF and a structured Excel workbook with 6 analysis sheets. Both are generated instantly and available for immediate download.
Where does the data come from?
Our database contains 1,900+ verified biopharma transactions sourced from SEC 8-K filings, FTC premerger filings, press releases, and regulatory databases. Data is updated daily.
Can I try before I buy?
Yes. Create a free account and get 3 calculations with headline deal term estimates. The $499 report unlocks the full analysis including rNPV with VaR/CVaR risk metrics, Monte Carlo simulation, multi-buyer valuation, partner matching with Pharma Intent scoring, and negotiation playbook.
Is there a subscription option?
Yes. Pro subscribers ($299/month) get unlimited reports, priority data access, and the Pharma Intent Score predictive model. The one-time report is ideal if you need a single comprehensive analysis.
How current is the data?
Our pipeline ingests new deals daily from SEC EDGAR, press releases, FTC filings, and clinical trial registries. Most major deals appear in our database within 24 hours of public disclosure.
Your next deal deserves
better data.
Select your asset parameters. See your deal benchmarks instantly. Unlock the full report for $499 — no page reload, no friction.
Configure your report
Select your asset parameters to generate a tailored analysis.
Free preview included · Full report $499 via Stripe